CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 28 enrolled
Drug / intervention
Ablationdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04170621
NCT04170621N/ACompleted

PersAFOne: Feasibility Study of the FARAPULSE™ Endocardial Ablation System in the Treatment of Persistent Atrial Fibrillation

Boston Scientific Corporation·interventional·Posted Nov 20, 2019·Updated Jan 30, 2024

In Brief

A clinical study evaluating Ablation for Persistent Atrial Fibrillation. Completed, enrolled 28 participants across 2 sites in 2 countries.

Detailed Summary

PersAFOne: Feasibility Study of the FARAPULSE™ Endocardial Ablation System in the Treatment of Persistent Atrial Fibrillation

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCroatia, Czechia
Collaborators--

Timeline

N/ACompletedFinished
2020202120222023202420252026
First PostedNov 20, 2019
Enrollment StartOct 18, 2019
Primary CompletionJul 14, 2021
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 6.6 years ago

Interventions

Ablationdevice

Ablation using the FARAPULSE Endocardial Multi Ablation System